BRPI0519085A2 - processos para a fabricaÇço de azd0530 e para a fabricaÇço de uma quinazolina, intermediÁrio, processo para a fabricaÇço de quinazolinona, forma cristalina substancialmente homogÊnea de 4-(6-cloro 2, 3-metileno-diàxi-anilino) - 7 - {2- (4-metil-piperazin -1- il) - etàxi} - 5 - tetraidropiran - 4-il- àxi - quinazolina, e, composiÇço farmacÊutica - Google Patents

processos para a fabricaÇço de azd0530 e para a fabricaÇço de uma quinazolina, intermediÁrio, processo para a fabricaÇço de quinazolinona, forma cristalina substancialmente homogÊnea de 4-(6-cloro 2, 3-metileno-diàxi-anilino) - 7 - {2- (4-metil-piperazin -1- il) - etàxi} - 5 - tetraidropiran - 4-il- àxi - quinazolina, e, composiÇço farmacÊutica

Info

Publication number
BRPI0519085A2
BRPI0519085A2 BRPI0519085-1A BRPI0519085A BRPI0519085A2 BR PI0519085 A2 BRPI0519085 A2 BR PI0519085A2 BR PI0519085 A BRPI0519085 A BR PI0519085A BR PI0519085 A2 BRPI0519085 A2 BR PI0519085A2
Authority
BR
Brazil
Prior art keywords
manufacture
quinazoline
processes
piperazin
chloro
Prior art date
Application number
BRPI0519085-1A
Other languages
English (en)
Inventor
James Gair Ford
James Francis Mccabe
Anne O'kearney-Mcmullan
Philip O'keefe
Simon Mark Pointon
Lyn Powell
Mark Purdie
Jane Withnall
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BRPI0519085A2 publication Critical patent/BRPI0519085A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

PROCESSOS PARA A FABRICAÇçO DE AZDO53O E PARA A FABRICAÇçO DE UMA QUINAZOLINA, INTERMEDIÁRIO, PROCESSO PARA A FABRICAÇçO DE QUINAZOLINONA, FORMA CRISTALINA SUBSTANCIALMENTE HOMOGÊNEA DE 4-(6- CLORO-2,3 -METILENO-DIàXI-ANILINO)-7- [2-(4-METIL-PIPERAZIN- 1 -IL)-ETàXI]-5-TETRAIDROPIRAN-4-IL-àXI-QUINAZOLINA, E, COMPOSIÇçO FARMACÊUTICA. A presente invenção refere-se aos processos químicos úteis na fabricação do composto 4-(6-cloro-2,3 -metileno-dióxi-anilino)-7- [2-(4-metil- piperazin- 1 -il)-etóxi]-5-tetraidropiran-4-il-óxi-quinazolina (a entidade ativa dentro de AZDO53O), aos intermediários úteis na fabricação daquele composto e aos processos para a fabricação daqueles intermediários. A invenção também se refere às formas cristalinas específicas daquele composto tal como um sal de difumarato e um tri-hidrato e às composições farmacêuticas contendo tais formas cristalinas.
BRPI0519085-1A 2004-12-17 2005-12-14 processos para a fabricaÇço de azd0530 e para a fabricaÇço de uma quinazolina, intermediÁrio, processo para a fabricaÇço de quinazolinona, forma cristalina substancialmente homogÊnea de 4-(6-cloro 2, 3-metileno-diàxi-anilino) - 7 - {2- (4-metil-piperazin -1- il) - etàxi} - 5 - tetraidropiran - 4-il- àxi - quinazolina, e, composiÇço farmacÊutica BRPI0519085A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0427697.8A GB0427697D0 (en) 2004-12-17 2004-12-17 Chemical process
PCT/GB2005/004807 WO2006064217A2 (en) 2004-12-17 2005-12-14 PROCESS FOR THE PREPARATION OF 4-(6-CHLORO-2, 3-METHYLENEDIOXYANILINO)-7-[2-(4-METHYLPIPERAZIN-l-YL) ETHOXY]-5-TETRAHYDROPYRAN-4-YLOXYQUINAZOLINE , THEIR INTERMEDIATES AND CRYSTALLINE SALTS THEREOF

Publications (1)

Publication Number Publication Date
BRPI0519085A2 true BRPI0519085A2 (pt) 2008-12-23

Family

ID=34090249

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519085-1A BRPI0519085A2 (pt) 2004-12-17 2005-12-14 processos para a fabricaÇço de azd0530 e para a fabricaÇço de uma quinazolina, intermediÁrio, processo para a fabricaÇço de quinazolinona, forma cristalina substancialmente homogÊnea de 4-(6-cloro 2, 3-metileno-diàxi-anilino) - 7 - {2- (4-metil-piperazin -1- il) - etàxi} - 5 - tetraidropiran - 4-il- àxi - quinazolina, e, composiÇço farmacÊutica

Country Status (16)

Country Link
US (1) US8304417B2 (pt)
EP (1) EP1871769B1 (pt)
JP (2) JP5161584B2 (pt)
KR (6) KR20070090004A (pt)
CN (1) CN101115744B (pt)
AU (2) AU2005315458B2 (pt)
BR (1) BRPI0519085A2 (pt)
CA (2) CA2590735C (pt)
ES (1) ES2622480T3 (pt)
GB (1) GB0427697D0 (pt)
IL (1) IL183525A0 (pt)
MX (1) MX2007007210A (pt)
NO (1) NO20072755L (pt)
NZ (1) NZ555468A (pt)
WO (1) WO2006064217A2 (pt)
ZA (1) ZA200704532B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0412074D0 (en) * 2004-05-29 2004-06-30 Astrazeneca Ab Combination product
WO2009068906A2 (en) * 2007-11-26 2009-06-04 Astrazeneca Ab Combinations comprising zd4054 and a src family kinase inhibitor 172
CN103275072B (zh) * 2013-05-22 2016-01-20 苏州明锐医药科技有限公司 塞卡替尼的制备方法
US10660957B2 (en) * 2013-06-13 2020-05-26 Yale University Compositions and methods for treating an Aβ-modulated disease or disorder or improving cognition in a subject
US11241434B2 (en) 2013-06-13 2022-02-08 Yale Uninversity Compositions and methods for improving cognition in a subject
WO2016130897A1 (en) 2015-02-13 2016-08-18 Yu Paul B Methods and compositions for the treatment or prevention of abnormal bone formation in a soft tissue
FI3930715T3 (fi) 2019-02-27 2024-08-05 Astrazeneca Ab Sarakatinibi käytettäväksi idiopaattisen keuhkofibroosin hoidossa
CN116332789A (zh) * 2023-03-10 2023-06-27 上海康鹏科技股份有限公司 一种4-氨基-2-氟苯甲酰胺的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73993C2 (uk) * 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
AU2001278609B2 (en) 2000-08-21 2005-04-14 Astrazeneca Ab Quinazoline derivatives
ATE409185T1 (de) 2001-04-19 2008-10-15 Astrazeneca Ab Chinazolin derivate
RU2350618C2 (ru) * 2002-11-04 2009-03-27 Астразенека Аб ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ
GB0226434D0 (en) 2002-11-13 2002-12-18 Astrazeneca Ab Combination product
GB0307333D0 (en) 2003-03-29 2003-05-07 Astrazeneca Ab Therapeutic agent
GB0309850D0 (en) * 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
GB0310401D0 (en) * 2003-05-07 2003-06-11 Astrazeneca Ab Therapeutic agent

Also Published As

Publication number Publication date
AU2009200622A1 (en) 2009-03-12
US8304417B2 (en) 2012-11-06
US20090099196A1 (en) 2009-04-16
KR20080094847A (ko) 2008-10-24
JP2008524183A (ja) 2008-07-10
ZA200704532B (en) 2008-07-30
KR20070090004A (ko) 2007-09-04
MX2007007210A (es) 2007-11-07
EP1871769B1 (en) 2017-02-22
NZ555468A (en) 2010-12-24
NO20072755L (no) 2007-07-02
JP5161584B2 (ja) 2013-03-13
EP1871769A2 (en) 2008-01-02
KR20110114727A (ko) 2011-10-19
CN101115744A (zh) 2008-01-30
AU2005315458B2 (en) 2009-03-12
KR20080094846A (ko) 2008-10-24
KR20080094849A (ko) 2008-10-24
WO2006064217A3 (en) 2006-12-21
WO2006064217A8 (en) 2007-07-05
CN101115744B (zh) 2012-02-01
IL183525A0 (en) 2007-09-20
WO2006064217A2 (en) 2006-06-22
ES2622480T3 (es) 2017-07-06
CA2590735A1 (en) 2006-06-22
KR20080094848A (ko) 2008-10-24
GB0427697D0 (en) 2005-01-19
JP2009143920A (ja) 2009-07-02
CA2590735C (en) 2009-11-10
CA2675642A1 (en) 2006-06-22
AU2005315458A1 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
BRPI0709633B8 (pt) derivados de piridina e pirimidina como antagonistas de mglur2, composição farmacêutica e uso dos mesmos
PE20121352A1 (es) Derivados de heteroarilo que contienen n como inhibidores de cinasa jak3
BRPI0919873B8 (pt) compostos de pirazol[1,5-a]pirimidina substituídos como inibidores da trk quinase, seus processos de preparação e composições farmacêuticas
PE20110545A1 (es) Compuestos de triazolopiridina como inhibidores de jak
MX2011005935A (es) Compuestos organicos.
ECSP088563A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
PE20090210A1 (es) Compuestos derivados de pirazolo pirimidina como inhibidores de jak quinasa
PE20060479A1 (es) Compuestos heteroaril-aril-ureas como inhibidores de la quinasa
MY152283A (en) Polo-like kinase inhibitirs
ATE400570T1 (de) 2,4,6-trisubstituierte pyrimidine als inhibitoren von phosphatidylinosit-(pi-)3-kinase und deren verwendung bei der behandlung von krebs
MY157871A (en) Mapk/erk kinase inhibitors
BRPI0611350B8 (pt) formulação, seus usos e seu processo de fabricação,e artigo de fabricação
BRPI0512335A (pt) compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades e sua utilização
AR031248A1 (es) Compuestos de ditosilato de quinazolina, composicion farmaceutica, metodo de tratamiento y uso en terapia y proceso para la preparacion de dichos compuestos
PE20130188A1 (es) Pirrolidinonas heteroaromaticas fusionadas como inhibidores de syk
PE20090288A1 (es) Derivados de quinoxalina como inhibidores de la pi3 quinasa
NO20085331L (no) Pyrazolo[1,5-A]pyrimidiner som CDK-inhibitorer
PE20091087A1 (es) COMPUESTOS DERIVADOS DE 6-FENIL-1H-IMIDAZO[4,5-c]PIRIDINA-4-CARBONITRILO COMO INHIBIDORES DE CATEPSINA S Y/O CATEPSINA K
TW200719886A (en) Dihydrobenzofuran derivatives and uses thereof
ATE554086T1 (de) Scopin-salze und deren verwendung in verfahren zur herstellung von n-demethyl-tiotropium und tiotropiumbromid
PE20090679A1 (es) Derivados de azaciclilisoquinolinona e isoindolinona como antagonistas de histamina-3
MX2011007444A (es) Derivados de quinazolinona utiles como antagonistas de vanilloides.
DOP2009000073A (es) Inhibidores de cinasa que catalizan la transferencia de fosforilo y/o que enlazan nucleótidos atp/gtp.
NO20072755L (no) Fremgangsmate for fremstilling av 4-(6-klor-2-metylendioksyanilino)-7-2-(4-metylpiperazin-1-yl)etoksy]-5-tetrahydropyran-4-yloksykinazolin, deres mellomprodukter og krystallinske salter derav
BR0316724A (pt) Compostos, uso de um ou mais compostos, e, processo para a fabricação de composições farmacêuticas

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.